Gadolinium — DTPA in magnetic resonance imaging of the brain

Abstract

This report concerns a clinical trial with Gd-DTPA as an intravenous contrast medium for MRI in patients with neurological disorders. 50 patients (30 female, 20 male) were examined without and with Gd-DTPA and the results of CT scanning and MR scanning without and with Gd-DTPA were compared. All patients tolerated the contrast medium very well. In the various patient groups, Gd-DTPA often added to the information. This was especially true in the tumor group, where better delineation of tumor, blood, and edema was obtained.

Intracranial Iotrolan Distribution Following Cervical Myelography

“…Other studies with iotrolan 240 to 300 mg I/ml demonstrated similar incidences, 24 to 52% (1, 2, 5, 9, 10, 13). By comparison, earlier series reported similar incidences with iohexol and iopamidol (8,10,15). HAMMER & DEISENHAMMER (5) found fewer side effects with 1330 mg I/ml than with 1800 mg I/ml iotrolan.…”